Osteoarthritis Drugs are Getting Better with Key Industry Leaders increasing Emphasis on Research and Development Activities
Osteoarthritis is a condition that occurs due to a gradual decrease in bone strength, which gradually results in the onset of degenerative conditions. This degenerative condition leads to painful and discomforting joints in the body. Although it can damage any joint, it usually affects the knees, hands, hips, and spine. According to the World Health Organization (WHO, by 2050, 20% of the global population will be aged 60 years and above, of which 15% is expected to have symptomatic osteoarthritis. There are different types of osteoarthritis drugs used to treat this chronic joint pain including Acetaminophen, Nonsteroidal anti-inflammatory drugs, Duloxetine, etc. Furthermore, there physical and occupational therapies used for the treatment of OA.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are over-the-counter medications that typically relieve osteoarthritis pain. However, a stronger version of NSAIDs is prescribed by physicians only. Acetaminophen has proven to be helping some people with osteoarthritis who have moderate pain. However, taking more than the recommended dose could lead to liver damage. Several studies are also conducted in order to study the effects of these medications in osteoarthritic conditions. The studies can be categorized as clinical trials, which involve volunteers, clinical trials, which are sponsored by drug companies, non-clinical trials, which include patients suffering from osteoarthritic conditions, and animal studies, which are conducted in laboratories.
A recent drug development that was recently released is the discovery of the CRICO-3, which is a new osteoarthritis drug. It is similar to CRICO-4 in its mechanism of action. It has been approved in Japan. In clinical trials, CRICO-3 was able to reduce the amount of bicarbonate produced by the kidney in the presence of low blood levels in the joint fluid. This in turn helped decrease the amount of calcium in the urine and decrease the release of arginine in the urine. Furthermore, in the U.S., the regulatory authorities approved a new experimental drug that could be used against arthritis.
Comments
Post a Comment